Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replacement,Treatment of dehydration,Intravenous infusion to provide calories and maintain blood glucose levels,Diluent for compatible medications
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Exogenous dextrose has a plasma half-life of approximately 15–20 minutes under normal metabolic conditions; in hyperglycemia or insulin resistance, half-life is prolonged.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the Krebs cycle to produce carbon dioxide, water, and energy. Sodium and chloride ions are excreted primarily by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Exogenous dextrose is fully metabolized to carbon dioxide and water; no significant renal or biliary excretion of intact dextrose. Sodium and chloride are primarily excreted renally (greater than 90% of filtered load reabsorbed; excess excreted in urine).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible (<5%) protein binding. Sodium and chloride: not protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: distributes into total body water, approximately 0.55–0.6 L/kg (in adults); sodium distributes primarily in extracellular fluid (0.2 L/kg).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% bioavailable. Not administered via oral, intramuscular, or subcutaneous routes for caloric or fluid replacement (oral dextrose has high first-pass metabolism).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific dose adjustment required; monitor fluid and electrolyte balance in renal impairment. In severe renal failure (GFR <15 m L/min), reduce volume to avoid fluid overload.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment required; monitor glucose and electrolytes in severe hepatic impairment due to risk of glucose intolerance.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 4-8 mg/kg/min dextrose for neonates, 100-150 m L/kg/day for infants, adjusting for fluid and electrolyte needs.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution; reduced renal function may require lower infusion rates and smaller volumes to avoid fluid overload. Monitor serum glucose and electrolytes closely.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA boxed warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hyperglycemia, especially in patients with diabetes mellitus,Monitor serum electrolytes and fluid balance to avoid hypernatremia or fluid overload,Contraindicated in patients with hypertonic dehydration, hypernatremia, or hyperglycemia with ketosis,Use with caution in patients with congestive heart failure, renal failure, or liver cirrhosis,Large volumes may cause electrolyte disturbances or osmotic diuresis
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypertonic dehydration,Hypernatremia,Severe hyperglycemia with ketosis,Known hypersensitivity to dextrose or sodium chloride,Intracranial or intraspinal hemorrhage (if administered via cerebrospinal fluid routes)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, concurrent administration of high-sugar or high-sodium foods may exacerbate hyperglycemia or hypernatremia. Monitor dietary intake of carbohydrates and sodium.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperinsulinism and neonatal hypoglycemia, particularly in third trimester. Hypoosmolar states from improper administration could impair placental perfusion.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose and sodium chloride are normal components of breast milk; no adverse effects expected at standard infusion rates. M/P ratio not applicable as endogenous substances.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Dose adjustments not typically required. Monitor glucose closely and reduce infusion rate or switch to lower dextrose concentration if hyperglycemia develops. Increased plasma volume in pregnancy may necessitate higher total fluid volumes to maintain euvolemia, but sodium content should be considered to avoid edema.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor serum glucose and electrolytes during prolonged infusion. Administer via large peripheral or central vein to prevent phlebitis. Use with caution in patients with renal impairment, heart failure, or hyperglycemia. Do not administer if solution is discolored or contains particulates. Incompatible with blood products via same line.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Inform your doctor if you have diabetes, heart failure, or kidney problems.,Report any signs of infusion site reactions like pain, redness, or swelling.,This solution contains sugar and salt; do not consume additional salt or sugar without medical advice.,You may need frequent blood tests to monitor your sugar and electrolyte levels.,Do not use this solution at home unless specifically instructed and trained.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support, replenishes glycogen stores, and prevents ketosis by supplying glucose for cellular energy metabolism. Sodium chloride maintains osmotic balance and replaces extracellular fluid and electrolytes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient fluid and electrolyte needs, typically 1-2 L/day in adults.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in 0.2% sodium chloride is a maintenance fluid; no teratogenic risk identified at standard doses. Maternal hyperglycemia from excessive dextrose may cause fetal hyperin. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.